Pembrolizumab + Lenvatinib

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Brain Metastases

Conditions

Brain Metastases, Tumor

Trial Timeline

Jan 20, 2022 → Feb 28, 2028

NCT ID

NCT05064280

About Pembrolizumab + Lenvatinib

Pembrolizumab + Lenvatinib is a phase 2 stage product being developed by Eisai for Brain Metastases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05064280. Target conditions include Brain Metastases, Tumor.

What happened to similar drugs?

5 of 18 similar drugs in Brain Metastases were approved

Approved (5) Terminated (2) Active (13)

✅ExenatideAstraZenecaApproved

✅RivastigmineNovartisApproved

✅Genotropin (PN-180,307) SomatropinPfizerApproved

✅Genotropin + PlaceboPfizerApproved

✅Dotarem® + Gadovist®/Gadavist®GuerbetApproved

🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05308901	Phase 2	Active	Aug 2, 2022	Jun 1, 2027	Melanoma, Uveal
NCT05064280	Phase 2	Recruiting	Jan 20, 2022	Feb 28, 2028	Brain Metastases
NCT04704219	Phase 2	Completed	Feb 23, 2021	Oct 21, 2025	Renal Cell Carcinoma
NCT03797326	Phase 2	Completed	Feb 12, 2019	Oct 28, 2024	Advanced Solid Tumors

Competing Products

20 competing products in Brain Metastases

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Endocrine therapy	Eli Lilly	Phase 1/2	39
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	27
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	29
Eribulin Mesylate	Eisai	Phase 1	29
Palonosetron (Aloxi) and Dexamethasone	Eisai	Phase 2	27
GLIADEL	Eisai	Phase 2	35
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim	Eli Lilly	Phase 1	29
abemaciclib + abemaciclib	Eli Lilly	Phase 2	39
JNJ-17299425	Johnson & Johnson	Phase 2	27
ABT-888	AbbVie	Phase 1	29
Veliparib + Placebo	AbbVie	Phase 2	35
Iressa (Gefitinib)	AstraZeneca	Phase 2	27
Trastuzumab deruxtecan	AstraZeneca	Phase 2	42
Exenatide	AstraZeneca	Approved	43
AZD5213	AstraZeneca	Phase 1	29
Vorinostat	Merck	Phase 1	29